244 related articles for article (PubMed ID: 29614520)
1. Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life Patients.
Kaserer A; Schedler A; Jetter A; Seifert B; Spahn DR; Stein P; Studt JD
Thromb Haemost; 2018 May; 118(5):808-817. PubMed ID: 29614520
[TBL] [Abstract][Full Text] [Related]
2. Impact of rivaroxaban plasma concentration on perioperative red blood cell loss.
Kaserer A; Kiavialaitis GE; Braun J; Schedler A; Stein P; Rössler J; Spahn DR; Studt JD
Transfusion; 2020 Jan; 60(1):197-205. PubMed ID: 31682296
[TBL] [Abstract][Full Text] [Related]
3. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
[TBL] [Abstract][Full Text] [Related]
4. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
[TBL] [Abstract][Full Text] [Related]
5. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
Siegmund HU; Burghaus R; Kubitza D; Coboeken K
Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
[TBL] [Abstract][Full Text] [Related]
6. Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.
Wiesen MHJ; Blaich C; Taubert M; Jennissen V; Streichert T; Pfister R; Michels G
Eur J Clin Pharmacol; 2018 May; 74(5):611-618. PubMed ID: 29376194
[TBL] [Abstract][Full Text] [Related]
7. Dose-finding study of rivaroxaban in hemodialysis patients.
De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
[TBL] [Abstract][Full Text] [Related]
8. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
[TBL] [Abstract][Full Text] [Related]
9. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Cheong EJ; Goh JJ; Hong Y; Venkatesan G; Liu Y; Chiu GN; Kojodjojo P; Chan EC
Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
[TBL] [Abstract][Full Text] [Related]
10. Standard coagulation assays alone are not sufficient to exclude surgically relevant rivaroxaban plasma concentrations.
Kaserer A; Schedler A; Seifert B; Spahn DR; Studt JD; Stein P
Perioper Med (Lond); 2019; 8():15. PubMed ID: 31832179
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects.
Brunner-Ziegler S; Jilma B; Schörgenhofer C; Winkler F; Jilma-Stohlawetz P; Koppensteiner R; Quehenberger P; Seger C; Weigel G; Griesmacher A; Brunner M
J Thromb Haemost; 2016 Feb; 14(2):316-23. PubMed ID: 26644369
[TBL] [Abstract][Full Text] [Related]
12. Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Greenblatt DJ; Patel M; Harmatz JS; Nicholson WT; Rubino CM; Chow CR
J Clin Pharmacol; 2018 Apr; 58(4):533-540. PubMed ID: 29194698
[TBL] [Abstract][Full Text] [Related]
13. Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation.
Wongcharoen W; Pacharasupa P; Norasetthada L; Gunaparn S; Phrommintikul A
Circ J; 2020 Jun; 84(7):1075-1082. PubMed ID: 32461505
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability.
Siguret V; Abdoul J; Delavenne X; Curis E; Carlo A; Blanchard A; Salem JE; Gaussem P; Funck-Brentano C; Azizi M; Mismetti P; Loriot MA; Lecompte T; Gouin-Thibault I
J Thromb Haemost; 2019 Oct; 17(10):1670-1682. PubMed ID: 31215111
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.
Asmis LM; Alberio L; Angelillo-Scherrer A; Korte W; Mendez A; Reber G; Seifert B; Stricker H; Tsakiris DA; Wuillemin WA
Thromb Res; 2012 Apr; 129(4):492-8. PubMed ID: 21840043
[TBL] [Abstract][Full Text] [Related]
17. Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation.
Escobar C; Arceluz M; Montes de Oca R; Mori R; López-Sendón JL; Merino JL
Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):121-122. PubMed ID: 27693025
[No Abstract] [Full Text] [Related]
18. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature.
Boissier E; Genebrier S; Lakhal K; Nedelec-Gac F; Trossaërt M; Ternisien C; Gouin-Thibault I
Thromb Haemost; 2018 Aug; 118(8):1488-1490. PubMed ID: 29960274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
